Kodiak is a high-science retinal medicines development company. We are aspiring to build a dominant global retina franchise. We are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness.
Our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. In our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments.